Strategies for pneumococcal vaccination in older adults in the coming era

Kei Nakashima,Wakaba Fukushima

DOI: https://doi.org/10.1080/21645515.2024.2328963

2024-03-24

Human Vaccines & Immunotherapeutics

Abstract:Pneumonia, predominantly caused by Streptococcus pneumoniae , remains a leading cause of global mortality. The 23-valent Pneumococcal polysaccharide vaccine (PPSV23) and conjugate vaccines (PCVs) are vital measures to fight against it. This paper discussed the changes in pneumococcal vaccination strategies, particularly for older adults, as vaccine effectiveness and epidemiological patterns shift. While PPSV23 maintains effectiveness against invasive pneumococcal disease (IPD), its effectiveness against pneumococcal pneumonia is declining. Conversely, PCV13 consistently demonstrates effectiveness against both IPD and pneumonia. Consequently, the US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommends using PCVs, notably PCV20 and PCV15, over PPSV23. Japanese studies indicate a change in the efficacy/effectiveness of PPSV23 following PCV introduction in children, likely owing to serotype replacement and herd immunity. Additionally, recent data reveals a plateau in the reduction of PCV13 and PPSV23-covered serotypes, posing a challenge to current strategies. This paper indicates a paradigm shift in pneumonia management, acknowledging its chronic nature and potential to exacerbate other diseases. The future of pneumococcal vaccination lies in broader serotype coverage through PCVs, adapting to serotype changes driven by childhood vaccination programs. Furthermore, continuous research and vaccine development are crucial in this evolving field.

immunology,biotechnology & applied microbiology

What problem does this paper attempt to address?

This paper mainly discusses the strategies for using pneumococcal vaccines in the elderly, particularly the new challenges arising from changes in vaccine efficacy and epidemiological patterns.

### Issues the paper attempts to address:

1. **Changes in vaccine efficacy**: The paper notes that the 23-valent pneumococcal polysaccharide vaccine (PPSV23) remains effective against invasive pneumococcal disease (IPD), but its efficacy against pneumococcal pneumonia is declining. In contrast, the 13-valent conjugate vaccine (PCV13) shows sustained efficacy against both types of diseases.

2. **Changes in vaccine recommendations**: The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommends prioritizing conjugate vaccines, especially the 20-valent pneumococcal conjugate vaccine (PCV20) and the 15-valent pneumococcal conjugate vaccine (PCV15), over PPSV23.

3. **Serotype replacement and herd immunity effects**: Studies in Japan have shown that the effectiveness of PPSV23 has changed following the introduction of pneumococcal conjugate vaccines in children, which may be related to serotype replacement and herd immunity.

4. **Future strategies**: The article discusses the shift in the paradigm of pneumonia management, recognizing pneumonia as a chronic disease that may exacerbate other conditions. Future pneumococcal vaccine strategies will focus on achieving broader serotype coverage through conjugate vaccines to adapt to serotype changes driven by pediatric vaccination programs.

5. **Cost-effectiveness analysis**: The article also mentions the results of cost-effectiveness analyses of different vaccines, indicating that using the PCV20 or PCV15+PPSV23 regimen can significantly reduce costs.

6. **Development of serotype-independent vaccines**: Given the phenomenon of serotype replacement, the article suggests that developing a broad-spectrum serotype-independent vaccine targeting highly conserved pneumococcal proteins is highly desirable.

In summary, this paper aims to explore the latest strategies for using pneumococcal vaccines in the elderly, particularly new directions in the face of challenges such as serotype replacement, herd immunity effects, and shifts in disease management concepts.